niacinamide has been researched along with Hepatopulmonary Syndrome in 4 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Hepatopulmonary Syndrome: A syndrome characterized by the clinical triad of advanced chronic liver disease, pulmonary vascular dilatations, and reduced arterial oxygenation (HYPOXEMIA) in the absence of intrinsic cardiopulmonary disease. This syndrome is common in the patients with LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib, a protein kinase inhibitor, is a systemic drug that has been licensed for the treatment of hepatocellular carcinoma (HCC)." | 9.16 | Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration. ( Bockisch, A; Ertle, J; Lauenstein, TC; Müller, S; Schlaak, JF; Schlosser, TW; Theysohn, JM, 2012) |
| "HPS (hepatopulmonary syndrome) is characterized by oxygen desaturation in patients with chronic liver disease." | 5.39 | Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis. ( Chang, CC; Chuang, CL; Hsieh, HG; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Teng, TH; Wang, SS, 2013) |
| "Sorafenib, a protein kinase inhibitor, is a systemic drug that has been licensed for the treatment of hepatocellular carcinoma (HCC)." | 5.16 | Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration. ( Bockisch, A; Ertle, J; Lauenstein, TC; Müller, S; Schlaak, JF; Schlosser, TW; Theysohn, JM, 2012) |
| "HPS (hepatopulmonary syndrome) is characterized by oxygen desaturation in patients with chronic liver disease." | 1.39 | Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis. ( Chang, CC; Chuang, CL; Hsieh, HG; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Teng, TH; Wang, SS, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baweja, S | 1 |
| Kumari, A | 1 |
| Negi, P | 1 |
| Tomar, A | 1 |
| Tripathi, DM | 1 |
| Mourya, AK | 1 |
| Rastogi, A | 1 |
| Subudhi, PD | 1 |
| Thangariyal, S | 1 |
| Kumar, G | 1 |
| Kumar, J | 1 |
| Reddy, GS | 1 |
| Sood, AK | 1 |
| Vashistha, C | 1 |
| Sarohi, V | 1 |
| Bihari, C | 1 |
| Maiwall, R | 1 |
| Sarin, SK | 1 |
| Yang, W | 1 |
| Zhang, J | 1 |
| Hu, B | 1 |
| Wu, W | 1 |
| Venter, J | 1 |
| Alpini, G | 1 |
| Fallon, MB | 1 |
| Theysohn, JM | 1 |
| Schlaak, JF | 1 |
| Müller, S | 1 |
| Ertle, J | 1 |
| Schlosser, TW | 1 |
| Bockisch, A | 1 |
| Lauenstein, TC | 1 |
| Chang, CC | 1 |
| Chuang, CL | 1 |
| Lee, FY | 1 |
| Wang, SS | 1 |
| Lin, HC | 1 |
| Huang, HC | 1 |
| Teng, TH | 1 |
| Hsu, SJ | 1 |
| Hsieh, HG | 1 |
| Lee, SD | 1 |
1 trial available for niacinamide and Hepatopulmonary Syndrome
| Article | Year |
|---|---|
Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatopulmonary Syndrom | 2012 |
3 other studies available for niacinamide and Hepatopulmonary Syndrome
| Article | Year |
|---|---|
Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod.
Topics: Animals; Fingolimod Hydrochloride; Hepatopulmonary Syndrome; Inflammation; Liver Cirrhosis; Mice; Ni | 2023 |
The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome.
Topics: Animals; Common Bile Duct; Disease Models, Animal; Endothelin-1; Endothelium, Vascular; Hepatopulmon | 2014 |
Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis.
Topics: Animals; Benzenesulfonates; Common Bile Duct; Disease Models, Animal; Hemodynamics; Hepatopulmonary | 2013 |